107 related articles for article (PubMed ID: 1463794)
1. Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine.
Karlsson M; Wikberg T
J Pharm Biomed Anal; 1992 Aug; 10(8):593-600. PubMed ID: 1463794
[TBL] [Abstract][Full Text] [Related]
2. Determination of a catechol-O-methyltransferase inhibitor, nitecapone, in human plasma and urine by liquid chromatography.
Wikberg T; Taskinen J
J Pharm Biomed Anal; 1991; 9(1):59-64. PubMed ID: 2043724
[TBL] [Abstract][Full Text] [Related]
3. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans.
Wikberg T; Vuorela A; Ottoila P; Taskinen J
Drug Metab Dispos; 1993; 21(1):81-92. PubMed ID: 8095232
[TBL] [Abstract][Full Text] [Related]
4. Micellar electrokinetic capillary chromatography method for direct determination of glucuronides of entacapone and its (Z)-isomer in human urine.
Lehtonen P; Lehtinen S; Mälkki-Laine L; Wikberg T
J Chromatogr A; 1999 Mar; 836(1):173-88. PubMed ID: 10220913
[TBL] [Abstract][Full Text] [Related]
5. Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog.
Wikberg T; Ottoila P; Taskinen J
Eur J Drug Metab Pharmacokinet; 1993; 18(4):359-67. PubMed ID: 8020535
[TBL] [Abstract][Full Text] [Related]
6. Metabolite profiles of two [14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile.
Wikberg T; Vuorela A
Eur J Drug Metab Pharmacokinet; 1994; 19(2):125-35. PubMed ID: 8001593
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
[TBL] [Abstract][Full Text] [Related]
8. High-performance liquid chromatography method for the quantification of entacapone in human plasma.
Ramakrishna NV; Vishwottam KN; Wishu S; Koteshwara M; Chidambara J
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Sep; 823(2):189-94. PubMed ID: 16009606
[TBL] [Abstract][Full Text] [Related]
9. Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection.
Timm U; Erdin R
J Chromatogr; 1992 Feb; 593(1-2):63-8. PubMed ID: 1639913
[TBL] [Abstract][Full Text] [Related]
10. Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS.
Yadav M; Dixit P; Trivedi V; Gandhi A; Senger A; Guttikar S; Singhal P; Shrivastav PS
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Feb; 877(5-6):533-40. PubMed ID: 19167276
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
[TBL] [Abstract][Full Text] [Related]
12. Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.
Bugamelli F; Marcheselli C; Barba E; Raggi MA
J Pharm Biomed Anal; 2011 Feb; 54(3):562-7. PubMed ID: 21035976
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a HPLC electrochemical detection method to measure COMT activity as a tool in drug development.
Viljoen FP; Preez JLD; Petzer A; Wessels JC; Petzer J; Aucamp ME
Pharmazie; 2019 May; 74(5):270-276. PubMed ID: 31109396
[TBL] [Abstract][Full Text] [Related]
14. Development of characterization methods for entacapone in a pharmaceutical bulk.
Soukhova N; Kassymbek Z; Bradby S; Martin-Esker A; White P; Wahab S
J Pharm Biomed Anal; 2011 Mar; 54(4):860-5. PubMed ID: 21112716
[TBL] [Abstract][Full Text] [Related]
15. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.
Nutt JG; Woodward WR; Beckner RM; Stone CK; Berggren K; Carter JH; Gancher ST; Hammerstad JP; Gordin A
Neurology; 1994 May; 44(5):913-9. PubMed ID: 8190296
[TBL] [Abstract][Full Text] [Related]
16. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
[TBL] [Abstract][Full Text] [Related]
17. Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease.
Li LS; Liu CZ; Xu JD; Zheng LF; Feng XY; Zhang Y; Zhu JX
World J Gastroenterol; 2015 Mar; 21(12):3509-18. PubMed ID: 25834315
[TBL] [Abstract][Full Text] [Related]
18. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.
Myllylä VV; Sotaniemi KA; Illi A; Suominen K; Keränen T
Eur J Clin Pharmacol; 1993; 45(5):419-23. PubMed ID: 8112370
[TBL] [Abstract][Full Text] [Related]
19. Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability.
Alqahtani S; Kaddoumi A
Biopharm Drug Dispos; 2015 Dec; 36(9):587-602. PubMed ID: 26295926
[TBL] [Abstract][Full Text] [Related]
20. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-L-dopa.
Pauwels T; Dethy S; Goldman S; Monclus M; Luxen A
Eur J Pharmacol; 1994 May; 257(1-2):53-8. PubMed ID: 8082707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
